Smith & Nephew plc (NYSE:SNN) Shares Sold by Riverwater Partners LLC

Riverwater Partners LLC cut its stake in Smith & Nephew plc (NYSE:SNN) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,347 shares of the medical equipment provider’s stock after selling 400 shares during the period. Riverwater Partners LLC’s holdings in Smith & Nephew were worth $314,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its position in shares of Smith & Nephew by 355.8% in the 2nd quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider’s stock worth $31,059,000 after acquiring an additional 964,762 shares in the last quarter. Brandes Investment Partners LP raised its stake in Smith & Nephew by 20.5% during the second quarter. Brandes Investment Partners LP now owns 1,373,051 shares of the medical equipment provider’s stock worth $34,002,000 after acquiring an additional 233,293 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Smith & Nephew by 58.2% in the second quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock worth $12,995,000 after acquiring an additional 193,046 shares during the last quarter. Tocqueville Asset Management L.P. raised its position in shares of Smith & Nephew by 294.9% during the 1st quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock worth $5,692,000 after purchasing an additional 167,599 shares during the period. Finally, Deprince Race & Zollo Inc. boosted its position in Smith & Nephew by 94.2% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 239,245 shares of the medical equipment provider’s stock valued at $5,928,000 after purchasing an additional 116,078 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft began coverage on Smith & Nephew in a research report on Wednesday, July 24th. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Smith & Nephew Price Performance

SNN stock opened at $29.23 on Thursday. Smith & Nephew plc has a 52 week low of $21.52 and a 52 week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The firm’s 50-day moving average is $30.35 and its two-hundred day moving average is $27.64.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.